Lukotas FX Tablet is a combination medication containing Montelukast 10 mg and Fexofenadine 120 mg, formulated for the management of allergic conditions such as allergic rhinitis and chronic urticaria. Montelukast, a leukotriene receptor antagonist, works by blocking leukotriene D4 receptors in the respiratory tract, thereby reducing inflammation, bronchoconstriction, and mucus production associated with allergic responses. Fexofenadine, a second-generation antihistamine, selectively inhibits peripheral H1 receptors, alleviating symptoms like sneezing, nasal congestion, itching, and hives without causing significant sedation. The synergistic action of these two agents provides comprehensive relief from allergic symptoms by targeting different pathways involved in the allergic cascade. Lukotas FX is indicated for patients requiring effective control of seasonal allergic rhinitis and chronic idiopathic urticaria, particularly when monotherapy is insufficient. It is generally well tolerated, with a low incidence of adverse effects such as headache, dizziness, or gastrointestinal discomfort. Caution is advised in patients with hepatic or renal impairment, and it should be used under medical supervision in pregnant or lactating women. Lukotas FX Tablet offers a convenient once-daily dosing regimen, enhancing patient compliance and improving quality of life in individuals suffering from allergic disorders.